Key result
Clinical inertia affected 54.3% of high-risk primary care patients and significantly increased the risk of remaining uncontrolled across any cardiovascular condition (RR 1.13).
Why the study?
Clinical inertia represents a major barrier to cardiovascular risk factor control, but its prevalence, patient-level predictors, and impact on risk factor outcomes in high-risk primary care patients needed evaluation.
Does clinical inertia prevent the achievement of cardiovascular risk factor control in high-risk primary care patients?
Observational (n=711)
Yes
Does clinical inertia prevent the achievement of cardiovascular risk factor control in high-risk primary care patients?
Clinical inertia is highly prevalent in primary care and significantly hinders the achievement of cardiovascular risk factor control, particularly for lipid management.
Clinical inertia was associated with poorer short-term control in primary care; supports prior observational data but leaves open causal effects and intervention trials.
Background: Clinical inertia, defined as the failure to initiate or intensify therapy when clinically indicated, represents a major and under-addressed barrier to achieving cardiovascular risk (CVR) factor control in primary care. Despite the availability of evidence-based guidelines and effective pharmacological treatments, many patients with uncontrolled hypertension, diabetes, or dyslipidaemia do not receive appropriate treatment intensification. We aimed to evaluate the prevalence of clinical inertia, identify associated patient-level factors, and assess its impact on CVR factor outcomes in high-risk primary care patients. Methods: This was a pre-specified secondary analysis of the Objetivo Punto de Mira (OPM) study, a multicentre, prospective, quasi-experimental interventional study conducted in primary care settings across nine Spanish regions (2024-2025). We included 711 participants with at least one uncontrolled CVR factor at baseline (hypertension, diabetes, or dyslipidaemia). Clinical inertia was operationalised, among therapeutically adherent patients, as the absence of documented pharmacological treatment initiation, dose escalation, or appropriate combination therapy when a risk factor remained uncontrolled. We estimated prevalence with 95% confidence intervals (CIs). Multivariable logistic regression identified factors associated with clinical inertia. Linear mixed-effects models assessed changes in CVR factors from baseline to 90-day follow-up, comparing patients with and without clinical inertia. Risk analysis quantified the association between clinical inertia and persistent uncontrolled status. Results: ; 95% CI = 0.02, 0.49, P = 0.036). Both groups showed significant within-group reductions in systolic and diastolic blood pressure (P < 0.001); however, the magnitude of change did not differ significantly between patients with and without clinical inertia (between-group interaction P > 0.05 for systolic blood pressure and diastolic blood pressure). We found no significant between-group differences for glycaemic parameters, high-density lipoprotein cholesterol, or triglycerides. Conclusions: Clinical inertia affects more than half of high-risk primary care patients with uncontrolled CVR factors. Patient demographic and clinical characteristics examined (age, sex, CVR category, excess weight) did not predict clinical inertia in this sample, consistent with, but not proof of, provider- and system-level influences described in prior literature.
No takes yet. Share an insight, caveat, or question.
Alemán et al. (2026) conducted an observational in Uncontrolled cardiovascular risk factors (hypertension, diabetes, or dyslipidaemia) (n=711). Clinical inertia vs. No clinical inertia (treatment intensification or modification) was evaluated on Persistent uncontrolled status across any condition at 90 days (RR 1.13, 95% CI 1.03, 1.24, p=0.007). Clinical inertia affected 54.3% of high-risk primary care patients and significantly increased the risk of remaining uncontrolled across any cardiovascular condition (RR 1.13).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: